nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—PTGS1—kidney cancer	0.217	0.636	CbGaD
Naproxen—PTGS2—kidney cancer	0.124	0.364	CbGaD
Naproxen—AKR1C3—Doxorubicin—kidney cancer	0.0879	0.228	CbGbCtD
Naproxen—UGT1A1—Pazopanib—kidney cancer	0.0673	0.175	CbGbCtD
Naproxen—UGT1A1—Erlotinib—kidney cancer	0.0481	0.125	CbGbCtD
Naproxen—UGT1A1—Sorafenib—kidney cancer	0.0391	0.101	CbGbCtD
Naproxen—CYP2C8—Pazopanib—kidney cancer	0.0197	0.0512	CbGbCtD
Naproxen—ALB—Erlotinib—kidney cancer	0.0182	0.0473	CbGbCtD
Naproxen—CYP1A2—Pazopanib—kidney cancer	0.0153	0.0396	CbGbCtD
Naproxen—CYP2C9—Capecitabine—kidney cancer	0.0144	0.0373	CbGbCtD
Naproxen—CYP2C8—Erlotinib—kidney cancer	0.0141	0.0365	CbGbCtD
Naproxen—CYP2C8—Paclitaxel—kidney cancer	0.0129	0.0335	CbGbCtD
Naproxen—CYP2C8—Sorafenib—kidney cancer	0.0114	0.0297	CbGbCtD
Naproxen—CYP1A2—Erlotinib—kidney cancer	0.0109	0.0283	CbGbCtD
Naproxen—CYP2C9—Paclitaxel—kidney cancer	0.00899	0.0233	CbGbCtD
Naproxen—CYP1A2—Sorafenib—kidney cancer	0.00886	0.023	CbGbCtD
Naproxen—CYP2C9—Sorafenib—kidney cancer	0.00799	0.0207	CbGbCtD
Naproxen—UGT1A1—urine—kidney cancer	0.00447	0.173	CbGeAlD
Naproxen—PTGS2—nephron—kidney cancer	0.00204	0.0789	CbGeAlD
Naproxen—CYP1A2—urine—kidney cancer	0.00198	0.0764	CbGeAlD
Naproxen—CYP2C9—urine—kidney cancer	0.00188	0.0725	CbGeAlD
Naproxen—AKR1C3—Vincristine—Vinblastine—kidney cancer	0.00141	0.554	CbGdCrCtD
Naproxen—AKR1C3—nephron tubule—kidney cancer	0.0013	0.0504	CbGeAlD
Naproxen—SLC22A6—nephron tubule—kidney cancer	0.0013	0.0502	CbGeAlD
Naproxen—UGT2B7—renal system—kidney cancer	0.00129	0.0497	CbGeAlD
Naproxen—UGT2B7—kidney—kidney cancer	0.00124	0.048	CbGeAlD
Naproxen—AKR1C3—Vinblastine—Vincristine—kidney cancer	0.00114	0.446	CbGdCrCtD
Naproxen—AKR1C3—cortex of kidney—kidney cancer	0.00112	0.0431	CbGeAlD
Naproxen—SLC22A6—cortex of kidney—kidney cancer	0.00111	0.0429	CbGeAlD
Naproxen—UGT1A1—renal system—kidney cancer	0.00109	0.0422	CbGeAlD
Naproxen—AKR1C3—cardiac atrium—kidney cancer	0.00106	0.041	CbGeAlD
Naproxen—UGT1A1—kidney—kidney cancer	0.00106	0.0408	CbGeAlD
Naproxen—SLCO1A2—renal system—kidney cancer	0.00074	0.0286	CbGeAlD
Naproxen—SLCO1A2—kidney—kidney cancer	0.000716	0.0277	CbGeAlD
Naproxen—Nabumetone—PTGS1—kidney cancer	0.000529	0.14	CrCbGaD
Naproxen—CYP2C8—renal system—kidney cancer	0.000517	0.02	CbGeAlD
Naproxen—Carprofen—PTGS1—kidney cancer	0.000505	0.133	CrCbGaD
Naproxen—CYP2C8—kidney—kidney cancer	0.0005	0.0193	CbGeAlD
Naproxen—CYP1A2—renal system—kidney cancer	0.000484	0.0187	CbGeAlD
Naproxen—PTGS1—renal system—kidney cancer	0.00042	0.0162	CbGeAlD
Naproxen—PTGS1—kidney—kidney cancer	0.000406	0.0157	CbGeAlD
Naproxen—PTGS2—renal system—kidney cancer	0.000401	0.0155	CbGeAlD
Naproxen—PTGS2—kidney—kidney cancer	0.000388	0.015	CbGeAlD
Naproxen—PTGS1—cardiac atrium—kidney cancer	0.000376	0.0145	CbGeAlD
Naproxen—Suprofen—PTGS1—kidney cancer	0.000312	0.0822	CrCbGaD
Naproxen—Nabumetone—PTGS2—kidney cancer	0.000302	0.0798	CrCbGaD
Naproxen—Carprofen—PTGS2—kidney cancer	0.000289	0.0761	CrCbGaD
Naproxen—Fenoprofen—PTGS1—kidney cancer	0.000269	0.0709	CrCbGaD
Naproxen—Indomethacin—PTGS1—kidney cancer	0.000198	0.0523	CrCbGaD
Naproxen—Suprofen—PTGS2—kidney cancer	0.000178	0.047	CrCbGaD
Naproxen—Flurbiprofen—PTGS1—kidney cancer	0.000175	0.0462	CrCbGaD
Naproxen—Ketoprofen—PTGS1—kidney cancer	0.000159	0.0418	CrCbGaD
Naproxen—Ibuprofen—PTGS1—kidney cancer	0.000156	0.0412	CrCbGaD
Naproxen—Fenoprofen—PTGS2—kidney cancer	0.000154	0.0405	CrCbGaD
Naproxen—Indomethacin—PTGS2—kidney cancer	0.000113	0.0299	CrCbGaD
Naproxen—Flurbiprofen—PTGS2—kidney cancer	0.0001	0.0264	CrCbGaD
Naproxen—Indomethacin—ABCB1—kidney cancer	9.64e-05	0.0254	CrCbGaD
Naproxen—Ketoprofen—PTGS2—kidney cancer	9.07e-05	0.0239	CrCbGaD
Naproxen—Ibuprofen—PTGS2—kidney cancer	8.93e-05	0.0235	CrCbGaD
Naproxen—Ibuprofen—ABCB1—kidney cancer	7.59e-05	0.02	CrCbGaD
Naproxen—Anaphylactic shock—Paclitaxel—kidney cancer	4.81e-05	0.000253	CcSEcCtD
Naproxen—Body temperature increased—Vincristine—kidney cancer	4.78e-05	0.000252	CcSEcCtD
Naproxen—Abdominal pain—Vincristine—kidney cancer	4.78e-05	0.000252	CcSEcCtD
Naproxen—Liver function test abnormal—Doxorubicin—kidney cancer	4.78e-05	0.000251	CcSEcCtD
Naproxen—Infection—Paclitaxel—kidney cancer	4.77e-05	0.000251	CcSEcCtD
Naproxen—Flatulence—Capecitabine—kidney cancer	4.76e-05	0.00025	CcSEcCtD
Naproxen—Dry skin—Doxorubicin—kidney cancer	4.74e-05	0.000249	CcSEcCtD
Naproxen—Dizziness—Sunitinib—kidney cancer	4.73e-05	0.000249	CcSEcCtD
Naproxen—Feeling abnormal—Gemcitabine—kidney cancer	4.73e-05	0.000249	CcSEcCtD
Naproxen—Shock—Paclitaxel—kidney cancer	4.73e-05	0.000249	CcSEcCtD
Naproxen—Vomiting—Sorafenib—kidney cancer	4.73e-05	0.000249	CcSEcCtD
Naproxen—Abdominal pain upper—Doxorubicin—kidney cancer	4.72e-05	0.000248	CcSEcCtD
Naproxen—Nervous system disorder—Paclitaxel—kidney cancer	4.71e-05	0.000248	CcSEcCtD
Naproxen—Hypokalaemia—Doxorubicin—kidney cancer	4.71e-05	0.000248	CcSEcCtD
Naproxen—Thrombocytopenia—Paclitaxel—kidney cancer	4.71e-05	0.000247	CcSEcCtD
Naproxen—Tachycardia—Paclitaxel—kidney cancer	4.69e-05	0.000247	CcSEcCtD
Naproxen—Rash—Sorafenib—kidney cancer	4.69e-05	0.000247	CcSEcCtD
Naproxen—Dermatitis—Sorafenib—kidney cancer	4.68e-05	0.000246	CcSEcCtD
Naproxen—Breast disorder—Doxorubicin—kidney cancer	4.67e-05	0.000246	CcSEcCtD
Naproxen—Skin disorder—Paclitaxel—kidney cancer	4.67e-05	0.000246	CcSEcCtD
Naproxen—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	4.66e-05	0.000245	CcSEcCtD
Naproxen—Headache—Sorafenib—kidney cancer	4.66e-05	0.000245	CcSEcCtD
Naproxen—Muscle spasms—Capecitabine—kidney cancer	4.65e-05	0.000244	CcSEcCtD
Naproxen—Hyperhidrosis—Paclitaxel—kidney cancer	4.65e-05	0.000244	CcSEcCtD
Naproxen—Diarrhoea—Dactinomycin—kidney cancer	4.63e-05	0.000244	CcSEcCtD
Naproxen—Anorexia—Paclitaxel—kidney cancer	4.58e-05	0.000241	CcSEcCtD
Naproxen—Gastritis—Doxorubicin—kidney cancer	4.58e-05	0.000241	CcSEcCtD
Naproxen—Muscular weakness—Doxorubicin—kidney cancer	4.56e-05	0.00024	CcSEcCtD
Naproxen—Vision blurred—Capecitabine—kidney cancer	4.55e-05	0.00024	CcSEcCtD
Naproxen—Vomiting—Sunitinib—kidney cancer	4.55e-05	0.000239	CcSEcCtD
Naproxen—Body temperature increased—Gemcitabine—kidney cancer	4.54e-05	0.000239	CcSEcCtD
Naproxen—Tremor—Capecitabine—kidney cancer	4.53e-05	0.000238	CcSEcCtD
Naproxen—Rash—Sunitinib—kidney cancer	4.51e-05	0.000237	CcSEcCtD
Naproxen—Dermatitis—Sunitinib—kidney cancer	4.51e-05	0.000237	CcSEcCtD
Naproxen—Abdominal distension—Doxorubicin—kidney cancer	4.5e-05	0.000237	CcSEcCtD
Naproxen—Hypotension—Paclitaxel—kidney cancer	4.49e-05	0.000236	CcSEcCtD
Naproxen—Ill-defined disorder—Capecitabine—kidney cancer	4.48e-05	0.000236	CcSEcCtD
Naproxen—Headache—Sunitinib—kidney cancer	4.48e-05	0.000236	CcSEcCtD
Naproxen—Influenza—Doxorubicin—kidney cancer	4.47e-05	0.000235	CcSEcCtD
Naproxen—Asthma—Doxorubicin—kidney cancer	4.47e-05	0.000235	CcSEcCtD
Naproxen—Dysphagia—Doxorubicin—kidney cancer	4.47e-05	0.000235	CcSEcCtD
Naproxen—Anaemia—Capecitabine—kidney cancer	4.47e-05	0.000235	CcSEcCtD
Naproxen—Hypersensitivity—Vincristine—kidney cancer	4.46e-05	0.000234	CcSEcCtD
Naproxen—Eosinophilia—Doxorubicin—kidney cancer	4.43e-05	0.000233	CcSEcCtD
Naproxen—Nausea—Sorafenib—kidney cancer	4.42e-05	0.000232	CcSEcCtD
Naproxen—Pancreatitis—Doxorubicin—kidney cancer	4.38e-05	0.000231	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Paclitaxel—kidney cancer	4.38e-05	0.00023	CcSEcCtD
Naproxen—Malaise—Capecitabine—kidney cancer	4.36e-05	0.000229	CcSEcCtD
Naproxen—Angina pectoris—Doxorubicin—kidney cancer	4.35e-05	0.000229	CcSEcCtD
Naproxen—Insomnia—Paclitaxel—kidney cancer	4.35e-05	0.000229	CcSEcCtD
Naproxen—Vertigo—Capecitabine—kidney cancer	4.34e-05	0.000228	CcSEcCtD
Naproxen—Asthenia—Vincristine—kidney cancer	4.34e-05	0.000228	CcSEcCtD
Naproxen—Syncope—Capecitabine—kidney cancer	4.33e-05	0.000228	CcSEcCtD
Naproxen—Leukopenia—Capecitabine—kidney cancer	4.33e-05	0.000227	CcSEcCtD
Naproxen—Paraesthesia—Paclitaxel—kidney cancer	4.32e-05	0.000227	CcSEcCtD
Naproxen—Vomiting—Dactinomycin—kidney cancer	4.31e-05	0.000226	CcSEcCtD
Naproxen—Bronchitis—Doxorubicin—kidney cancer	4.3e-05	0.000226	CcSEcCtD
Naproxen—Dyspnoea—Paclitaxel—kidney cancer	4.28e-05	0.000225	CcSEcCtD
Naproxen—Somnolence—Paclitaxel—kidney cancer	4.27e-05	0.000225	CcSEcCtD
Naproxen—Palpitations—Capecitabine—kidney cancer	4.27e-05	0.000225	CcSEcCtD
Naproxen—Rash—Dactinomycin—kidney cancer	4.27e-05	0.000225	CcSEcCtD
Naproxen—Nausea—Sunitinib—kidney cancer	4.25e-05	0.000223	CcSEcCtD
Naproxen—Loss of consciousness—Capecitabine—kidney cancer	4.25e-05	0.000223	CcSEcCtD
Naproxen—Pancytopenia—Doxorubicin—kidney cancer	4.25e-05	0.000223	CcSEcCtD
Naproxen—Dyspepsia—Paclitaxel—kidney cancer	4.23e-05	0.000222	CcSEcCtD
Naproxen—Cough—Capecitabine—kidney cancer	4.22e-05	0.000222	CcSEcCtD
Naproxen—Dysuria—Doxorubicin—kidney cancer	4.18e-05	0.00022	CcSEcCtD
Naproxen—Decreased appetite—Paclitaxel—kidney cancer	4.18e-05	0.00022	CcSEcCtD
Naproxen—Hypertension—Capecitabine—kidney cancer	4.17e-05	0.000219	CcSEcCtD
Naproxen—Gastrointestinal disorder—Paclitaxel—kidney cancer	4.15e-05	0.000218	CcSEcCtD
Naproxen—Fatigue—Paclitaxel—kidney cancer	4.14e-05	0.000218	CcSEcCtD
Naproxen—Diarrhoea—Vincristine—kidney cancer	4.14e-05	0.000218	CcSEcCtD
Naproxen—Pollakiuria—Doxorubicin—kidney cancer	4.13e-05	0.000217	CcSEcCtD
Naproxen—Asthenia—Gemcitabine—kidney cancer	4.12e-05	0.000217	CcSEcCtD
Naproxen—Myalgia—Capecitabine—kidney cancer	4.11e-05	0.000216	CcSEcCtD
Naproxen—Arthralgia—Capecitabine—kidney cancer	4.11e-05	0.000216	CcSEcCtD
Naproxen—Chest pain—Capecitabine—kidney cancer	4.11e-05	0.000216	CcSEcCtD
Naproxen—Constipation—Paclitaxel—kidney cancer	4.11e-05	0.000216	CcSEcCtD
Naproxen—Pain—Paclitaxel—kidney cancer	4.11e-05	0.000216	CcSEcCtD
Naproxen—Anxiety—Capecitabine—kidney cancer	4.1e-05	0.000216	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	4.09e-05	0.000215	CcSEcCtD
Naproxen—Photosensitivity reaction—Doxorubicin—kidney cancer	4.08e-05	0.000215	CcSEcCtD
Naproxen—Discomfort—Capecitabine—kidney cancer	4.06e-05	0.000214	CcSEcCtD
Naproxen—Pruritus—Gemcitabine—kidney cancer	4.06e-05	0.000214	CcSEcCtD
Naproxen—Weight decreased—Doxorubicin—kidney cancer	4.04e-05	0.000213	CcSEcCtD
Naproxen—Hyperglycaemia—Doxorubicin—kidney cancer	4.03e-05	0.000212	CcSEcCtD
Naproxen—Dry mouth—Capecitabine—kidney cancer	4.02e-05	0.000212	CcSEcCtD
Naproxen—Nausea—Dactinomycin—kidney cancer	4.02e-05	0.000212	CcSEcCtD
Naproxen—Pneumonia—Doxorubicin—kidney cancer	4.01e-05	0.000211	CcSEcCtD
Naproxen—Dizziness—Vincristine—kidney cancer	4e-05	0.00021	CcSEcCtD
Naproxen—Drowsiness—Doxorubicin—kidney cancer	3.99e-05	0.00021	CcSEcCtD
Naproxen—Confusional state—Capecitabine—kidney cancer	3.98e-05	0.000209	CcSEcCtD
Naproxen—Feeling abnormal—Paclitaxel—kidney cancer	3.96e-05	0.000208	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	3.95e-05	0.000208	CcSEcCtD
Naproxen—Oedema—Capecitabine—kidney cancer	3.94e-05	0.000207	CcSEcCtD
Naproxen—Gastrointestinal pain—Paclitaxel—kidney cancer	3.93e-05	0.000207	CcSEcCtD
Naproxen—Diarrhoea—Gemcitabine—kidney cancer	3.93e-05	0.000207	CcSEcCtD
Naproxen—Renal failure—Doxorubicin—kidney cancer	3.92e-05	0.000206	CcSEcCtD
Naproxen—Infection—Capecitabine—kidney cancer	3.92e-05	0.000206	CcSEcCtD
Naproxen—Neuropathy peripheral—Doxorubicin—kidney cancer	3.91e-05	0.000205	CcSEcCtD
Naproxen—Stomatitis—Doxorubicin—kidney cancer	3.89e-05	0.000204	CcSEcCtD
Naproxen—Jaundice—Doxorubicin—kidney cancer	3.89e-05	0.000204	CcSEcCtD
Naproxen—Shock—Capecitabine—kidney cancer	3.88e-05	0.000204	CcSEcCtD
Naproxen—Urinary tract infection—Doxorubicin—kidney cancer	3.87e-05	0.000204	CcSEcCtD
Naproxen—Conjunctivitis—Doxorubicin—kidney cancer	3.87e-05	0.000204	CcSEcCtD
Naproxen—Nervous system disorder—Capecitabine—kidney cancer	3.87e-05	0.000203	CcSEcCtD
Naproxen—Thrombocytopenia—Capecitabine—kidney cancer	3.86e-05	0.000203	CcSEcCtD
Naproxen—Tachycardia—Capecitabine—kidney cancer	3.85e-05	0.000202	CcSEcCtD
Naproxen—Vomiting—Vincristine—kidney cancer	3.85e-05	0.000202	CcSEcCtD
Naproxen—Skin disorder—Capecitabine—kidney cancer	3.83e-05	0.000201	CcSEcCtD
Naproxen—Sweating—Doxorubicin—kidney cancer	3.82e-05	0.000201	CcSEcCtD
Naproxen—Urticaria—Paclitaxel—kidney cancer	3.82e-05	0.000201	CcSEcCtD
Naproxen—Rash—Vincristine—kidney cancer	3.82e-05	0.000201	CcSEcCtD
Naproxen—Hyperhidrosis—Capecitabine—kidney cancer	3.81e-05	0.000201	CcSEcCtD
Naproxen—Dermatitis—Vincristine—kidney cancer	3.81e-05	0.0002	CcSEcCtD
Naproxen—Haematuria—Doxorubicin—kidney cancer	3.8e-05	0.0002	CcSEcCtD
Naproxen—Abdominal pain—Paclitaxel—kidney cancer	3.8e-05	0.0002	CcSEcCtD
Naproxen—Body temperature increased—Paclitaxel—kidney cancer	3.8e-05	0.0002	CcSEcCtD
Naproxen—Headache—Vincristine—kidney cancer	3.79e-05	0.000199	CcSEcCtD
Naproxen—Hepatobiliary disease—Doxorubicin—kidney cancer	3.77e-05	0.000198	CcSEcCtD
Naproxen—Epistaxis—Doxorubicin—kidney cancer	3.76e-05	0.000198	CcSEcCtD
Naproxen—Anorexia—Capecitabine—kidney cancer	3.76e-05	0.000198	CcSEcCtD
Naproxen—Sinusitis—Doxorubicin—kidney cancer	3.74e-05	0.000197	CcSEcCtD
Naproxen—Agranulocytosis—Doxorubicin—kidney cancer	3.72e-05	0.000196	CcSEcCtD
Naproxen—Hypotension—Capecitabine—kidney cancer	3.69e-05	0.000194	CcSEcCtD
Naproxen—Vomiting—Gemcitabine—kidney cancer	3.65e-05	0.000192	CcSEcCtD
Naproxen—Rash—Gemcitabine—kidney cancer	3.62e-05	0.00019	CcSEcCtD
Naproxen—Dermatitis—Gemcitabine—kidney cancer	3.62e-05	0.00019	CcSEcCtD
Naproxen—Haemoglobin—Doxorubicin—kidney cancer	3.6e-05	0.000189	CcSEcCtD
Naproxen—Headache—Gemcitabine—kidney cancer	3.6e-05	0.000189	CcSEcCtD
Naproxen—Nausea—Vincristine—kidney cancer	3.59e-05	0.000189	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Capecitabine—kidney cancer	3.59e-05	0.000189	CcSEcCtD
Naproxen—Rhinitis—Doxorubicin—kidney cancer	3.59e-05	0.000189	CcSEcCtD
Naproxen—Haemorrhage—Doxorubicin—kidney cancer	3.58e-05	0.000188	CcSEcCtD
Naproxen—Hepatitis—Doxorubicin—kidney cancer	3.58e-05	0.000188	CcSEcCtD
Naproxen—Insomnia—Capecitabine—kidney cancer	3.57e-05	0.000188	CcSEcCtD
Naproxen—Pharyngitis—Doxorubicin—kidney cancer	3.55e-05	0.000187	CcSEcCtD
Naproxen—Paraesthesia—Capecitabine—kidney cancer	3.54e-05	0.000186	CcSEcCtD
Naproxen—Hypersensitivity—Paclitaxel—kidney cancer	3.54e-05	0.000186	CcSEcCtD
Naproxen—Urinary tract disorder—Doxorubicin—kidney cancer	3.53e-05	0.000186	CcSEcCtD
Naproxen—Oedema peripheral—Doxorubicin—kidney cancer	3.53e-05	0.000185	CcSEcCtD
Naproxen—Connective tissue disorder—Doxorubicin—kidney cancer	3.52e-05	0.000185	CcSEcCtD
Naproxen—Dyspnoea—Capecitabine—kidney cancer	3.52e-05	0.000185	CcSEcCtD
Naproxen—Urethral disorder—Doxorubicin—kidney cancer	3.51e-05	0.000184	CcSEcCtD
Naproxen—Dyspepsia—Capecitabine—kidney cancer	3.47e-05	0.000183	CcSEcCtD
Naproxen—Visual impairment—Doxorubicin—kidney cancer	3.45e-05	0.000181	CcSEcCtD
Naproxen—Asthenia—Paclitaxel—kidney cancer	3.45e-05	0.000181	CcSEcCtD
Naproxen—Decreased appetite—Capecitabine—kidney cancer	3.43e-05	0.00018	CcSEcCtD
Naproxen—Nausea—Gemcitabine—kidney cancer	3.41e-05	0.000179	CcSEcCtD
Naproxen—Gastrointestinal disorder—Capecitabine—kidney cancer	3.41e-05	0.000179	CcSEcCtD
Naproxen—Fatigue—Capecitabine—kidney cancer	3.4e-05	0.000179	CcSEcCtD
Naproxen—Pruritus—Paclitaxel—kidney cancer	3.4e-05	0.000179	CcSEcCtD
Naproxen—Erythema multiforme—Doxorubicin—kidney cancer	3.38e-05	0.000178	CcSEcCtD
Naproxen—Pain—Capecitabine—kidney cancer	3.37e-05	0.000177	CcSEcCtD
Naproxen—Constipation—Capecitabine—kidney cancer	3.37e-05	0.000177	CcSEcCtD
Naproxen—Eye disorder—Doxorubicin—kidney cancer	3.34e-05	0.000176	CcSEcCtD
Naproxen—Tinnitus—Doxorubicin—kidney cancer	3.34e-05	0.000175	CcSEcCtD
Naproxen—Cardiac disorder—Doxorubicin—kidney cancer	3.32e-05	0.000175	CcSEcCtD
Naproxen—Diarrhoea—Paclitaxel—kidney cancer	3.29e-05	0.000173	CcSEcCtD
Naproxen—Feeling abnormal—Capecitabine—kidney cancer	3.25e-05	0.000171	CcSEcCtD
Naproxen—Angiopathy—Doxorubicin—kidney cancer	3.25e-05	0.000171	CcSEcCtD
Naproxen—Immune system disorder—Doxorubicin—kidney cancer	3.23e-05	0.00017	CcSEcCtD
Naproxen—Gastrointestinal pain—Capecitabine—kidney cancer	3.23e-05	0.00017	CcSEcCtD
Naproxen—Mediastinal disorder—Doxorubicin—kidney cancer	3.23e-05	0.00017	CcSEcCtD
Naproxen—Chills—Doxorubicin—kidney cancer	3.21e-05	0.000169	CcSEcCtD
Naproxen—Arrhythmia—Doxorubicin—kidney cancer	3.2e-05	0.000168	CcSEcCtD
Naproxen—Dizziness—Paclitaxel—kidney cancer	3.18e-05	0.000167	CcSEcCtD
Naproxen—Alopecia—Doxorubicin—kidney cancer	3.16e-05	0.000166	CcSEcCtD
Naproxen—Mental disorder—Doxorubicin—kidney cancer	3.14e-05	0.000165	CcSEcCtD
Naproxen—Urticaria—Capecitabine—kidney cancer	3.13e-05	0.000165	CcSEcCtD
Naproxen—Abdominal pain—Capecitabine—kidney cancer	3.12e-05	0.000164	CcSEcCtD
Naproxen—Body temperature increased—Capecitabine—kidney cancer	3.12e-05	0.000164	CcSEcCtD
Naproxen—Malnutrition—Doxorubicin—kidney cancer	3.12e-05	0.000164	CcSEcCtD
Naproxen—Erythema—Doxorubicin—kidney cancer	3.12e-05	0.000164	CcSEcCtD
Naproxen—Flatulence—Doxorubicin—kidney cancer	3.07e-05	0.000161	CcSEcCtD
Naproxen—Tension—Doxorubicin—kidney cancer	3.06e-05	0.000161	CcSEcCtD
Naproxen—Vomiting—Paclitaxel—kidney cancer	3.06e-05	0.000161	CcSEcCtD
Naproxen—Rash—Paclitaxel—kidney cancer	3.03e-05	0.000159	CcSEcCtD
Naproxen—Dermatitis—Paclitaxel—kidney cancer	3.03e-05	0.000159	CcSEcCtD
Naproxen—Nervousness—Doxorubicin—kidney cancer	3.03e-05	0.000159	CcSEcCtD
Naproxen—Headache—Paclitaxel—kidney cancer	3.01e-05	0.000158	CcSEcCtD
Naproxen—Muscle spasms—Doxorubicin—kidney cancer	2.99e-05	0.000158	CcSEcCtD
Naproxen—Vision blurred—Doxorubicin—kidney cancer	2.94e-05	0.000154	CcSEcCtD
Naproxen—Hypersensitivity—Capecitabine—kidney cancer	2.91e-05	0.000153	CcSEcCtD
Naproxen—Ill-defined disorder—Doxorubicin—kidney cancer	2.89e-05	0.000152	CcSEcCtD
Naproxen—Anaemia—Doxorubicin—kidney cancer	2.88e-05	0.000151	CcSEcCtD
Naproxen—Nausea—Paclitaxel—kidney cancer	2.85e-05	0.00015	CcSEcCtD
Naproxen—Asthenia—Capecitabine—kidney cancer	2.83e-05	0.000149	CcSEcCtD
Naproxen—Malaise—Doxorubicin—kidney cancer	2.81e-05	0.000148	CcSEcCtD
Naproxen—Vertigo—Doxorubicin—kidney cancer	2.8e-05	0.000147	CcSEcCtD
Naproxen—Syncope—Doxorubicin—kidney cancer	2.79e-05	0.000147	CcSEcCtD
Naproxen—Pruritus—Capecitabine—kidney cancer	2.79e-05	0.000147	CcSEcCtD
Naproxen—Leukopenia—Doxorubicin—kidney cancer	2.79e-05	0.000147	CcSEcCtD
Naproxen—Palpitations—Doxorubicin—kidney cancer	2.75e-05	0.000145	CcSEcCtD
Naproxen—Loss of consciousness—Doxorubicin—kidney cancer	2.74e-05	0.000144	CcSEcCtD
Naproxen—Cough—Doxorubicin—kidney cancer	2.72e-05	0.000143	CcSEcCtD
Naproxen—Convulsion—Doxorubicin—kidney cancer	2.7e-05	0.000142	CcSEcCtD
Naproxen—Diarrhoea—Capecitabine—kidney cancer	2.7e-05	0.000142	CcSEcCtD
Naproxen—Hypertension—Doxorubicin—kidney cancer	2.69e-05	0.000141	CcSEcCtD
Naproxen—Myalgia—Doxorubicin—kidney cancer	2.65e-05	0.000139	CcSEcCtD
Naproxen—Arthralgia—Doxorubicin—kidney cancer	2.65e-05	0.000139	CcSEcCtD
Naproxen—Chest pain—Doxorubicin—kidney cancer	2.65e-05	0.000139	CcSEcCtD
Naproxen—Anxiety—Doxorubicin—kidney cancer	2.64e-05	0.000139	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	2.63e-05	0.000139	CcSEcCtD
Naproxen—Discomfort—Doxorubicin—kidney cancer	2.62e-05	0.000138	CcSEcCtD
Naproxen—Dizziness—Capecitabine—kidney cancer	2.61e-05	0.000137	CcSEcCtD
Naproxen—Dry mouth—Doxorubicin—kidney cancer	2.59e-05	0.000136	CcSEcCtD
Naproxen—Confusional state—Doxorubicin—kidney cancer	2.56e-05	0.000135	CcSEcCtD
Naproxen—Oedema—Doxorubicin—kidney cancer	2.54e-05	0.000134	CcSEcCtD
Naproxen—Anaphylactic shock—Doxorubicin—kidney cancer	2.54e-05	0.000134	CcSEcCtD
Naproxen—Infection—Doxorubicin—kidney cancer	2.53e-05	0.000133	CcSEcCtD
Naproxen—Vomiting—Capecitabine—kidney cancer	2.51e-05	0.000132	CcSEcCtD
Naproxen—Shock—Doxorubicin—kidney cancer	2.5e-05	0.000132	CcSEcCtD
Naproxen—Nervous system disorder—Doxorubicin—kidney cancer	2.49e-05	0.000131	CcSEcCtD
Naproxen—Thrombocytopenia—Doxorubicin—kidney cancer	2.49e-05	0.000131	CcSEcCtD
Naproxen—Rash—Capecitabine—kidney cancer	2.49e-05	0.000131	CcSEcCtD
Naproxen—Dermatitis—Capecitabine—kidney cancer	2.48e-05	0.000131	CcSEcCtD
Naproxen—Tachycardia—Doxorubicin—kidney cancer	2.48e-05	0.00013	CcSEcCtD
Naproxen—Headache—Capecitabine—kidney cancer	2.47e-05	0.00013	CcSEcCtD
Naproxen—Skin disorder—Doxorubicin—kidney cancer	2.47e-05	0.00013	CcSEcCtD
Naproxen—Hyperhidrosis—Doxorubicin—kidney cancer	2.46e-05	0.000129	CcSEcCtD
Naproxen—Anorexia—Doxorubicin—kidney cancer	2.42e-05	0.000127	CcSEcCtD
Naproxen—Hypotension—Doxorubicin—kidney cancer	2.38e-05	0.000125	CcSEcCtD
Naproxen—Nausea—Capecitabine—kidney cancer	2.34e-05	0.000123	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Doxorubicin—kidney cancer	2.32e-05	0.000122	CcSEcCtD
Naproxen—Insomnia—Doxorubicin—kidney cancer	2.3e-05	0.000121	CcSEcCtD
Naproxen—Paraesthesia—Doxorubicin—kidney cancer	2.28e-05	0.00012	CcSEcCtD
Naproxen—Dyspnoea—Doxorubicin—kidney cancer	2.27e-05	0.000119	CcSEcCtD
Naproxen—Somnolence—Doxorubicin—kidney cancer	2.26e-05	0.000119	CcSEcCtD
Naproxen—Dyspepsia—Doxorubicin—kidney cancer	2.24e-05	0.000118	CcSEcCtD
Naproxen—Decreased appetite—Doxorubicin—kidney cancer	2.21e-05	0.000116	CcSEcCtD
Naproxen—Gastrointestinal disorder—Doxorubicin—kidney cancer	2.19e-05	0.000115	CcSEcCtD
Naproxen—Fatigue—Doxorubicin—kidney cancer	2.19e-05	0.000115	CcSEcCtD
Naproxen—Constipation—Doxorubicin—kidney cancer	2.17e-05	0.000114	CcSEcCtD
Naproxen—Pain—Doxorubicin—kidney cancer	2.17e-05	0.000114	CcSEcCtD
Naproxen—Feeling abnormal—Doxorubicin—kidney cancer	2.1e-05	0.00011	CcSEcCtD
Naproxen—Gastrointestinal pain—Doxorubicin—kidney cancer	2.08e-05	0.000109	CcSEcCtD
Naproxen—Urticaria—Doxorubicin—kidney cancer	2.02e-05	0.000106	CcSEcCtD
Naproxen—Body temperature increased—Doxorubicin—kidney cancer	2.01e-05	0.000106	CcSEcCtD
Naproxen—Abdominal pain—Doxorubicin—kidney cancer	2.01e-05	0.000106	CcSEcCtD
Naproxen—Hypersensitivity—Doxorubicin—kidney cancer	1.87e-05	9.85e-05	CcSEcCtD
Naproxen—Asthenia—Doxorubicin—kidney cancer	1.82e-05	9.59e-05	CcSEcCtD
Naproxen—Pruritus—Doxorubicin—kidney cancer	1.8e-05	9.46e-05	CcSEcCtD
Naproxen—Diarrhoea—Doxorubicin—kidney cancer	1.74e-05	9.15e-05	CcSEcCtD
Naproxen—Dizziness—Doxorubicin—kidney cancer	1.68e-05	8.84e-05	CcSEcCtD
Naproxen—Vomiting—Doxorubicin—kidney cancer	1.62e-05	8.5e-05	CcSEcCtD
Naproxen—Rash—Doxorubicin—kidney cancer	1.6e-05	8.43e-05	CcSEcCtD
Naproxen—Dermatitis—Doxorubicin—kidney cancer	1.6e-05	8.42e-05	CcSEcCtD
Naproxen—Headache—Doxorubicin—kidney cancer	1.59e-05	8.38e-05	CcSEcCtD
Naproxen—Nausea—Doxorubicin—kidney cancer	1.51e-05	7.94e-05	CcSEcCtD
Naproxen—AKR1C3—Signaling Pathways—KDR—kidney cancer	1.19e-05	0.000233	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTGS2—kidney cancer	1.19e-05	0.000233	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—RAF1—kidney cancer	1.19e-05	0.000231	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GLIPR1—kidney cancer	1.17e-05	0.000228	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PPAT—kidney cancer	1.17e-05	0.000228	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CA2—kidney cancer	1.16e-05	0.000227	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GSTM1—kidney cancer	1.16e-05	0.000227	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	1.16e-05	0.000225	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—SCARB1—kidney cancer	1.15e-05	0.000223	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	1.14e-05	0.000223	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	1.14e-05	0.000223	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALAD—kidney cancer	1.14e-05	0.000221	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CRABP1—kidney cancer	1.13e-05	0.000221	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CDKN1B—kidney cancer	1.13e-05	0.00022	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.12e-05	0.000218	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PSMD7—kidney cancer	1.11e-05	0.000217	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ST3GAL2—kidney cancer	1.11e-05	0.000216	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	1.1e-05	0.000215	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CYP1A1—kidney cancer	1.1e-05	0.000215	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GSTP1—kidney cancer	1.1e-05	0.000215	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—APC—kidney cancer	1.1e-05	0.000215	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KIT—kidney cancer	1.1e-05	0.000215	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.09e-05	0.000212	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—APRT—kidney cancer	1.09e-05	0.000212	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—FH—kidney cancer	1.09e-05	0.000212	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CA9—kidney cancer	1.08e-05	0.000212	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALDH1A1—kidney cancer	1.08e-05	0.000211	CbGpPWpGaD
Naproxen—ALB—Metabolism—CA9—kidney cancer	1.08e-05	0.00021	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CTNNB1—kidney cancer	1.07e-05	0.000208	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	1.06e-05	0.000207	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.06e-05	0.000207	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—BCHE—kidney cancer	1.05e-05	0.000206	CbGpPWpGaD
Naproxen—PTGS2—Disease—PSMD7—kidney cancer	1.05e-05	0.000206	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.05e-05	0.000206	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ITPR2—kidney cancer	1.05e-05	0.000206	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—VEGFA—kidney cancer	1.05e-05	0.000205	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—POMC—kidney cancer	1.05e-05	0.000204	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ABCB1—kidney cancer	1.04e-05	0.000204	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—SLC5A5—kidney cancer	1.04e-05	0.000203	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTEN—kidney cancer	1.04e-05	0.000203	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PGK1—kidney cancer	1.04e-05	0.000202	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SLC5A3—kidney cancer	1.04e-05	0.000202	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—BRAF—kidney cancer	1.03e-05	0.000202	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GSTP1—kidney cancer	1.03e-05	0.000201	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GPC3—kidney cancer	1.02e-05	0.0002	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—LDHB—kidney cancer	1.02e-05	0.000199	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GSTM1—kidney cancer	1.01e-05	0.000198	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—SLC2A1—kidney cancer	1.01e-05	0.000196	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTGS2—kidney cancer	9.99e-06	0.000195	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CA2—kidney cancer	9.95e-06	0.000194	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	9.95e-06	0.000194	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	9.76e-06	0.00019	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ABCB1—kidney cancer	9.74e-06	0.00019	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	9.71e-06	0.000189	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALAD—kidney cancer	9.7e-06	0.000189	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ACHE—kidney cancer	9.61e-06	0.000187	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTT1—kidney cancer	9.61e-06	0.000187	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CYP1A1—kidney cancer	9.61e-06	0.000187	CbGpPWpGaD
Naproxen—PTGS2—Disease—SLC2A1—kidney cancer	9.54e-06	0.000186	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	9.47e-06	0.000185	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ST3GAL2—kidney cancer	9.47e-06	0.000185	CbGpPWpGaD
Naproxen—PTGS2—Disease—JUNB—kidney cancer	9.47e-06	0.000185	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GSTM1—kidney cancer	9.46e-06	0.000184	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALDH1A1—kidney cancer	9.25e-06	0.00018	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CRABP1—kidney cancer	9.22e-06	0.00018	CbGpPWpGaD
Naproxen—ALB—Metabolism—CRABP1—kidney cancer	9.17e-06	0.000179	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—SCARB1—kidney cancer	9.1e-06	0.000177	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PTGS1—kidney cancer	9e-06	0.000176	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CYP1A1—kidney cancer	8.97e-06	0.000175	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MAPK3—kidney cancer	8.88e-06	0.000173	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC5A3—kidney cancer	8.87e-06	0.000173	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PGK1—kidney cancer	8.87e-06	0.000173	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PSMD7—kidney cancer	8.83e-06	0.000172	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CA9—kidney cancer	8.83e-06	0.000172	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTEN—kidney cancer	8.71e-06	0.00017	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—LDHB—kidney cancer	8.7e-06	0.00017	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MYC—kidney cancer	8.64e-06	0.000169	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—RAF1—kidney cancer	8.63e-06	0.000168	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	8.63e-06	0.000168	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—RELA—kidney cancer	8.59e-06	0.000168	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ITPR2—kidney cancer	8.57e-06	0.000167	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ERBB2—kidney cancer	8.54e-06	0.000167	CbGpPWpGaD
Naproxen—ALB—Metabolism—ITPR2—kidney cancer	8.52e-06	0.000166	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	8.51e-06	0.000166	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MAPK1—kidney cancer	8.45e-06	0.000165	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MTOR—kidney cancer	8.43e-06	0.000164	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GSTP1—kidney cancer	8.39e-06	0.000164	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—BCHE—kidney cancer	8.37e-06	0.000163	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—SLC5A5—kidney cancer	8.27e-06	0.000161	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—POMC—kidney cancer	8.23e-06	0.00016	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	8.22e-06	0.00016	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—SLC2A1—kidney cancer	7.99e-06	0.000156	CbGpPWpGaD
Naproxen—AKR1C3—Disease—KRAS—kidney cancer	7.98e-06	0.000156	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ABCB1—kidney cancer	7.94e-06	0.000155	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CDKN1B—kidney cancer	7.91e-06	0.000154	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—POMC—kidney cancer	7.9e-06	0.000154	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	7.89e-06	0.000154	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—POMC—kidney cancer	7.86e-06	0.000153	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTT1—kidney cancer	7.82e-06	0.000152	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ACHE—kidney cancer	7.82e-06	0.000152	CbGpPWpGaD
Naproxen—ALB—Metabolism—ACHE—kidney cancer	7.77e-06	0.000152	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTT1—kidney cancer	7.77e-06	0.000152	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL2—kidney cancer	7.74e-06	0.000151	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GSTM1—kidney cancer	7.71e-06	0.00015	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN2B—kidney cancer	7.71e-06	0.00015	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCND1—kidney cancer	7.54e-06	0.000147	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CA9—kidney cancer	7.54e-06	0.000147	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—JUN—kidney cancer	7.53e-06	0.000147	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CRABP1—kidney cancer	7.51e-06	0.000146	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CTNNB1—kidney cancer	7.47e-06	0.000146	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—SCARB1—kidney cancer	7.4e-06	0.000144	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	7.37e-06	0.000144	CbGpPWpGaD
Naproxen—ALB—Metabolism—SCARB1—kidney cancer	7.36e-06	0.000144	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PIK3CA—kidney cancer	7.34e-06	0.000143	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS1—kidney cancer	7.33e-06	0.000143	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CYP1A1—kidney cancer	7.31e-06	0.000143	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS1—kidney cancer	7.28e-06	0.000142	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PTEN—kidney cancer	7.28e-06	0.000142	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PSMD7—kidney cancer	7.18e-06	0.00014	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—POMC—kidney cancer	7.16e-06	0.00014	CbGpPWpGaD
Naproxen—ALB—Metabolism—PSMD7—kidney cancer	7.14e-06	0.000139	CbGpPWpGaD
Naproxen—ALB—Hemostasis—RAF1—kidney cancer	7.12e-06	0.000139	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ITPR2—kidney cancer	6.98e-06	0.000136	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—BCHE—kidney cancer	6.81e-06	0.000133	CbGpPWpGaD
Naproxen—ALB—Metabolism—BCHE—kidney cancer	6.77e-06	0.000132	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	6.76e-06	0.000132	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—SLC5A5—kidney cancer	6.73e-06	0.000131	CbGpPWpGaD
Naproxen—ALB—Metabolism—SLC5A5—kidney cancer	6.69e-06	0.00013	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—POMC—kidney cancer	6.68e-06	0.00013	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTP1—kidney cancer	6.66e-06	0.00013	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VEGFA—kidney cancer	6.58e-06	0.000128	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGS2—kidney cancer	6.56e-06	0.000128	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—SLC2A1—kidney cancer	6.5e-06	0.000127	CbGpPWpGaD
Naproxen—ALB—Metabolism—SLC2A1—kidney cancer	6.46e-06	0.000126	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.43e-06	0.000125	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CRABP1—kidney cancer	6.41e-06	0.000125	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IL2—kidney cancer	6.38e-06	0.000124	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ACHE—kidney cancer	6.36e-06	0.000124	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTT1—kidney cancer	6.36e-06	0.000124	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ABCB1—kidney cancer	6.3e-06	0.000123	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	6.3e-06	0.000123	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	6.27e-06	0.000122	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MAPK3—kidney cancer	6.22e-06	0.000121	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—RAF1—kidney cancer	6.16e-06	0.00012	CbGpPWpGaD
Naproxen—PTGS2—Disease—HIF1A—kidney cancer	6.16e-06	0.00012	CbGpPWpGaD
Naproxen—PTGS2—Disease—TSC2—kidney cancer	6.14e-06	0.00012	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PIK3CA—kidney cancer	6.14e-06	0.00012	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTM1—kidney cancer	6.12e-06	0.000119	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MYC—kidney cancer	6.05e-06	0.000118	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SCARB1—kidney cancer	6.02e-06	0.000117	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6e-06	0.000117	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ITPR2—kidney cancer	5.96e-06	0.000116	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS1—kidney cancer	5.96e-06	0.000116	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MAPK1—kidney cancer	5.92e-06	0.000115	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PSMD7—kidney cancer	5.85e-06	0.000114	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP1A1—kidney cancer	5.8e-06	0.000113	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTEN—kidney cancer	5.72e-06	0.000112	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—kidney cancer	5.71e-06	0.000111	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KRAS—kidney cancer	5.59e-06	0.000109	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—BCHE—kidney cancer	5.54e-06	0.000108	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.5e-06	0.000107	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.5e-06	0.000107	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SLC5A5—kidney cancer	5.48e-06	0.000107	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.47e-06	0.000107	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—POMC—kidney cancer	5.45e-06	0.000106	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTT1—kidney cancer	5.44e-06	0.000106	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ACHE—kidney cancer	5.44e-06	0.000106	CbGpPWpGaD
Naproxen—PTGS2—Disease—APC—kidney cancer	5.43e-06	0.000106	CbGpPWpGaD
Naproxen—PTGS2—Disease—KIT—kidney cancer	5.43e-06	0.000106	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—kidney cancer	5.42e-06	0.000106	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTP1—kidney cancer	5.42e-06	0.000106	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTP1—kidney cancer	5.39e-06	0.000105	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—kidney cancer	5.33e-06	0.000104	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SLC2A1—kidney cancer	5.29e-06	0.000103	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SCARB1—kidney cancer	5.15e-06	0.0001	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CA—kidney cancer	5.14e-06	0.0001	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.13e-06	0.0001	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MAPK3—kidney cancer	5.13e-06	0.0001	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ABCB1—kidney cancer	5.13e-06	0.0001	CbGpPWpGaD
Naproxen—PTGS2—Disease—BRAF—kidney cancer	5.1e-06	9.95e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—ABCB1—kidney cancer	5.1e-06	9.95e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS1—kidney cancer	5.1e-06	9.94e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PSMD7—kidney cancer	5e-06	9.75e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTEN—kidney cancer	4.98e-06	9.72e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTM1—kidney cancer	4.98e-06	9.71e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—kidney cancer	4.97e-06	9.69e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTM1—kidney cancer	4.95e-06	9.66e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MAPK1—kidney cancer	4.88e-06	9.52e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.77e-06	9.3e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—BCHE—kidney cancer	4.74e-06	9.24e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP1A1—kidney cancer	4.72e-06	9.21e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP1A1—kidney cancer	4.69e-06	9.16e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC5A5—kidney cancer	4.68e-06	9.13e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTEN—kidney cancer	4.65e-06	9.07e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—KRAS—kidney cancer	4.61e-06	8.99e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC2A1—kidney cancer	4.52e-06	8.81e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.47e-06	8.73e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTP1—kidney cancer	4.41e-06	8.6e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.38e-06	8.55e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—kidney cancer	4.35e-06	8.48e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—POMC—kidney cancer	4.33e-06	8.44e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—RAF1—kidney cancer	4.26e-06	8.31e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CA—kidney cancer	4.24e-06	8.26e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—ERBB2—kidney cancer	4.21e-06	8.22e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ABCB1—kidney cancer	4.18e-06	8.14e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MTOR—kidney cancer	4.16e-06	8.11e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD4—kidney cancer	4.15e-06	8.1e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—kidney cancer	4.1e-06	7.99e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTM1—kidney cancer	4.05e-06	7.91e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CA—kidney cancer	4.04e-06	7.87e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN1B—kidney cancer	3.9e-06	7.61e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.88e-06	7.56e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.86e-06	7.52e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP1A1—kidney cancer	3.84e-06	7.49e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.82e-06	7.46e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTEN—kidney cancer	3.79e-06	7.39e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTP1—kidney cancer	3.77e-06	7.35e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CTNNB1—kidney cancer	3.69e-06	7.19e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PTEN—kidney cancer	3.59e-06	7.01e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ABCB1—kidney cancer	3.57e-06	6.96e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—POMC—kidney cancer	3.52e-06	6.87e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CA—kidney cancer	3.52e-06	6.86e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—POMC—kidney cancer	3.5e-06	6.83e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTM1—kidney cancer	3.46e-06	6.76e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP1A1—kidney cancer	3.28e-06	6.4e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CA—kidney cancer	3.28e-06	6.4e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.16e-06	6.16e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAPK3—kidney cancer	3.07e-06	5.99e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PTEN—kidney cancer	3.01e-06	5.87e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MYC—kidney cancer	2.99e-06	5.82e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAPK1—kidney cancer	2.92e-06	5.7e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—POMC—kidney cancer	2.86e-06	5.59e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—kidney cancer	2.81e-06	5.48e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—kidney cancer	2.79e-06	5.44e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—KRAS—kidney cancer	2.76e-06	5.38e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.7e-06	5.26e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CA—kidney cancer	2.67e-06	5.22e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CA—kidney cancer	2.53e-06	4.94e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTEN—kidney cancer	2.45e-06	4.78e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—POMC—kidney cancer	2.45e-06	4.77e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTEN—kidney cancer	2.43e-06	4.75e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—kidney cancer	2.29e-06	4.46e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CA—kidney cancer	2.12e-06	4.14e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTEN—kidney cancer	1.99e-06	3.89e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—kidney cancer	1.95e-06	3.81e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CA—kidney cancer	1.73e-06	3.37e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CA—kidney cancer	1.72e-06	3.35e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTEN—kidney cancer	1.7e-06	3.32e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.41e-06	2.74e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.2e-06	2.34e-05	CbGpPWpGaD
